1. Home
  2. TNGX vs EM Comparison

TNGX vs EM Comparison

Compare TNGX & EM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • EM
  • Stock Information
  • Founded
  • TNGX 2014
  • EM 2017
  • Country
  • TNGX United States
  • EM China
  • Employees
  • TNGX N/A
  • EM N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • EM Other Consumer Services
  • Sector
  • TNGX Health Care
  • EM Consumer Discretionary
  • Exchange
  • TNGX Nasdaq
  • EM Nasdaq
  • Market Cap
  • TNGX 351.2M
  • EM 289.1M
  • IPO Year
  • TNGX N/A
  • EM 2021
  • Fundamental
  • Price
  • TNGX $5.88
  • EM $1.13
  • Analyst Decision
  • TNGX Strong Buy
  • EM Hold
  • Analyst Count
  • TNGX 6
  • EM 1
  • Target Price
  • TNGX $12.20
  • EM $1.25
  • AVG Volume (30 Days)
  • TNGX 2.6M
  • EM 97.4K
  • Earning Date
  • TNGX 08-06-2025
  • EM 08-21-2025
  • Dividend Yield
  • TNGX N/A
  • EM N/A
  • EPS Growth
  • TNGX N/A
  • EM N/A
  • EPS
  • TNGX N/A
  • EM N/A
  • Revenue
  • TNGX $40,990,000.00
  • EM $259,541,587.00
  • Revenue This Year
  • TNGX N/A
  • EM $3.30
  • Revenue Next Year
  • TNGX N/A
  • EM $5.26
  • P/E Ratio
  • TNGX N/A
  • EM N/A
  • Revenue Growth
  • TNGX 10.09
  • EM N/A
  • 52 Week Low
  • TNGX $1.03
  • EM $0.50
  • 52 Week High
  • TNGX $12.02
  • EM $1.17
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 73.28
  • EM 56.54
  • Support Level
  • TNGX $5.75
  • EM $1.12
  • Resistance Level
  • TNGX $6.40
  • EM $1.16
  • Average True Range (ATR)
  • TNGX 0.50
  • EM 0.02
  • MACD
  • TNGX -0.03
  • EM -0.00
  • Stochastic Oscillator
  • TNGX 83.80
  • EM 30.00

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About EM Smart Share Global Limited

Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.

Share on Social Networks: